1-2 of 2
Ann Janssens
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial

Open Access
Clinical Trials & Observations
Carsten U. Niemann, Julie Dubois, Kazem Nasserinejad, Caspar da Cunha-Bang, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H.M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Johan A. Dobber, Christian B. Poulsen, Wida Razawy, René Hollestein, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling, Juha Ranti, Christian Brieghel, Mattias Mattsson, Mar Bellido, Hoa T. T. Tran, Arnon P. Kater, Mark-David Levin
Journal: Blood Advances
Blood Adv (2025) 9 (15): 3665–3675.
https://doi.org/10.1182/bloodadvances.2024015180
Published: 2025
Includes: Supplemental data
Journal Articles

Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

Free
Clinical Trials & Observations
Loretta J. Nastoupil, Georg Hess, Miguel A. Pavlovsky, Iwona Danielewicz, Jane Freeman, Alejandro Martin García-Sancho, Valeria Glazunova, Andrew Grigg, Jing-Zhou Hou, Ann Janssens, Seok Jin Kim, Zvenyslava Masliak, Pam McKay, Francesco Merli, Wataru Munakata, Hirokazu Nagai, Muhit Özcan, Meir Preis, Tingyu Wang, Melissa Rowe, Monelle Tamegnon, Rui Qin, Todd Henninger, Madeliene Curtis, Donne Bennett Caces, Catherine Thieblemont, Gilles Salles
Journal: Blood Advances
Blood Adv (2023) 7 (22): 7141–7150.
https://doi.org/10.1182/bloodadvances.2023010298
Published: 2023
Includes: Supplemental data